Unknown

Dataset Information

0

A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication.


ABSTRACT:

Background

Macroscopic complete resection can improve survival in a select group of patients with malignant pleural mesothelioma. During resection, differentiating residual tumor from inflammation or scar can be challenging. This trial evaluated near-infrared (NIR) intraoperative imaging using TumorGlow (a novel NIR imaging approach utilizing high-dose indocyanine green and delayed imaging) technology to improve detection of macroscopic residual disease.

Methods

Twenty subjects were enrolled in an open-label clinical trial of NIR intraoperative imaging with TumorGlow (Indocyanine Green for Solid Tumors [NCT02280954]). Twenty-four hours before pleural biopsy or pleurectomy and decortication (P/D), patients received intravenous indocyanine green. All specimens identified during standard-of-care surgical resection and with NIR imaging underwent histopathologic profiling and correlative microscopic fluorescent tomographic evaluation. For subjects undergoing P/D (n = 13), the hemithorax was evaluated with NIR imaging during P/D to assess for residual disease. When possible, additional fluorescent lesions were resected.

Results

Of 203 resected specimens submitted for evaluation, indocyanine green accumulated within 113 of 113 of resected mesothelioma specimens, with a mean signal-to-background fluorescence ratio of 3.1 (SD, 2.2 to 4.8). The mean signal-to-background fluorescence ratio of benign tissues was 2.2 (SD, 1.4 to 2.4), which was significantly lower than in malignant specimens (p = 0.001). NIR imaging identified occult macroscopic residual disease in 10 of 13 subjects. A median of 5.6 resectable residual deposits per patient (range, 0 to 11 deposits per patient), with a mean size of 0.3 cm (range, 0.1 to 1.5 cm), were identified.

Conclusions

TumorGlow for malignant pleural mesothelioma is safe and feasible. Excellent sensitivity allows for to reliable detection of macroscopic residual disease during cytoreductive surgical procedures.

SUBMITTER: Predina JD 

PROVIDER: S-EPMC6296901 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication.

Predina Jarrod D JD   Newton Andrew D AD   Corbett Christopher C   Xia Leilei L   Shin Michael M   Sulfyok Lydia Frenzel LF   Okusanya Olugbenga T OT   Cengel Keith A KA   Haas Andrew A   Litzky Leslie L   Kucharczuk John C JC   Singhal Sunil S  

The Annals of thoracic surgery 20180717 1


<h4>Background</h4>Macroscopic complete resection can improve survival in a select group of patients with malignant pleural mesothelioma. During resection, differentiating residual tumor from inflammation or scar can be challenging. This trial evaluated near-infrared (NIR) intraoperative imaging using TumorGlow (a novel NIR imaging approach utilizing high-dose indocyanine green and delayed imaging) technology to improve detection of macroscopic residual disease.<h4>Methods</h4>Twenty subjects we  ...[more]

Similar Datasets

| S-EPMC5394041 | biostudies-literature
| S-EPMC7467531 | biostudies-literature
| S-EPMC8312143 | biostudies-literature
| S-EPMC10859178 | biostudies-literature
| S-EPMC9989816 | biostudies-literature
| S-EPMC8474452 | biostudies-literature
| S-EPMC6378119 | biostudies-literature
| S-EPMC5568093 | biostudies-literature
| S-EPMC9571799 | biostudies-literature
| S-EPMC6267825 | biostudies-other